Lader M
Institute of Psychiatry, London, U.K.
J Psychosom Res. 1994;38 Suppl 1:113-23; discussion 118-23. doi: 10.1016/0022-3999(94)90142-2.
The prescription of hypnotics, mostly benzodiazepines, continues at a high level, long-, medium- and short-acting compounds all being used. The indication for these hypnotics is the symptom of insomnia which is often secondary to a primary anxiety or depressive disorder. One problem with the use of hypnotics, particularly shorter-acting ones, is rebound insomnia in that discontinuation may be followed by sleep which is worse than pretreatment levels. Anxiety, which may well have been assuaged by the hypnotic treatment, may also rebound but depression, usually not really helped by the hypnotic, does not alter much. A second problem, on discontinuation of long-term treatment, particularly longer-acting hypnotics, is a physical withdrawal syndrome characterized by general malaise, and perceptual symptoms as well as marked increases in anxiety and insomnia. In some patients, however, depressive symptoms predominate. These may be an exaggeration of an on-going depressive disorder or it may appear to arise de novo in patients hitherto free of such an illness. The depression can be quite severe and need rigorous treatment in its own right. It is always useful to enquire about hypnotic/anxiolytic withdrawal in patients presenting with a depressive disorder. Depression is also a prognostic indicator of poor outcome (failure to withdraw successfully) in patients taking benzodiazepine hypnotics chronically.
催眠药(主要是苯二氮䓬类药物)的处方量持续居高不下,长效、中效和短效化合物均有使用。这些催眠药的适应证是失眠症状,而失眠往往继发于原发性焦虑或抑郁障碍。使用催眠药,尤其是短效催眠药时存在的一个问题是反弹性失眠,即停药后睡眠可能比治疗前更差。催眠治疗可能缓解的焦虑也可能出现反弹,但通常对抑郁没有真正帮助的催眠药,不会使抑郁有太大变化。长期治疗停药时,尤其是长效催眠药,第二个问题是出现身体戒断综合征,其特征为全身不适、感知症状以及焦虑和失眠明显加重。然而,在一些患者中,抑郁症状占主导。这些症状可能是正在进行的抑郁障碍的加重,也可能在既往无此类疾病的患者中看似新发。这种抑郁可能相当严重,本身就需要严格治疗。对于患有抑郁障碍的患者,询问其催眠药/抗焦虑药戒断情况总是很有用的。抑郁也是长期服用苯二氮䓬类催眠药的患者预后不良(未能成功停药)的一个预后指标。